ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2744

Altered Expression of CD52 Facilitates Adhesion of Circulating CD14+ Monocytes in Systemic Sclerosis

Michal Rudnik1, Mara Stellato 1, Filip Rolski 2, Przemyslaw Blyszczuk 3, Karin Klingel 4, Joerg Henes 5, Carol Feghali-Bostwick 6, Oliver Distler 7 and Gabriela Kania 3, 1Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 2Department of Clinical Immunology, Jagiellonian University Medical College, Krakow, Poland, 3Centre of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 4Institute for Pathology and Neuropathology, University Hospital Tuebingen, Tuebingen, Germany, 5University Hospital Tuebingen, Department of Internal Medicine II (Oncology, Haematology, Immunology and Rheumatology), Tuebingen, Germany, 6Division of Rheumatology & Immunology, Medical University of South Carolina, Charlston, SC, 7Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: adhesion molecules and monocytes, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: 5T095: Systemic Sclerosis & Related Disorder – Basic Science (2744–2749)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Infiltration of inflammatory cells, including monocytes, into the organs is a major process leading to fibrosis, remodelling and organ dysfunction in systemic sclerosis (SSc). Adhesion is a key process for cell infiltration. However, its pathomechanisms in SSc remain elusive.

CD52 protein is highly expressed on CD4+ T-cells and plays an important role in the modulation of T-cell receptor signalling. Nevertheless, the function of this protein on monocytes is not completely understood.

We aimed to investigate the process of monocyte adhesion in SSc with a special focus on the influence of CD52 expression.

Methods: Biopsies from the heart, lungs and skin of SSc patients (n=11, 7, 7, respectively) and healthy controls (HC) (n=10, 7, 9, respectively) were analysed by immunohistochemistry for the presence of CD14+ cells. RNAseq of CD14+ blood monocytes of lcSSc (n=5, age=54.4±6.7), dcSSc patients (n=5, age=51.8±7.2) and age- and sex-matched HC (n=5, age=50.8±9.7) was performed. Differentially expressed genes were computed using DeSEQ2 algorithm. Gene ontology and pathway analysis were performed using Metacore software and ShinyApp. Expression of adhesion molecules was confirmed by flow cytometry (HC n=16, SSc n =76). Adhesion of CD14+ monocytes to ICAM1 and TNFα-stimulated endothelial cells was checked using the 96-well plate adhesion assay (HC n=12, SSc n=40). CD52 regulation in CD14+ monocytes from HC (n=4) was analysed on mRNA level upon stimulation with LPS, IFNγ, IL-4 and IL-13. Adhesion under the physiological shear flow of THP-1 cell lines with overexpression and silencing of CD52 was investigated (n=4).

Results: Immunohistochemistry confirmed higher infiltration of CD14+ cells in the heart (p< 0.01), lung (p< 0.05) and skin (p< 0.001) of SSc patients. 1440 differentially expressed genes were detected between dcSSc vs HC and 225 between lcSSc and HC (p≤0.01; log2 ratio≥0.5). Pathway analysis revealed significant alterations in adhesion and chemotaxis pathways. Flow cytometry confirmed upregulation of adhesion molecules CD11b (p< 0.01) and CD18 (p< 0.05). In contrast, expression of CD52 was downregulated in SSc patients (p< 0.05). SSc CD14+ monocytes exhibited increased adhesion both to ICAM1-coated plates (p< 0.01) and to TNFα-stimulated endothelial cells (p< 0.05). CD52 mRNA was increased in a dose-dependent manner after IL-4 and IL-13 stimulation and decreased after LPS and IFNγ stimulation (p< 0.05). Overexpression of CD52 in THP-1 monocytes decreased adhesion to TNFα-stimulated endothelial cells (p< 0.01) under the shear flow conditions. Accordingly, silencing of CD52 increased adhesion of THP-1 monocytes (p< 0.01).

Conclusion: Here we pointed to an increased adhesion of peripheral blood CD14+ monocytes to ICAM1 and endothelial cells in SSc. Our results suggest the primary activation of monocytes in peripheral blood, which may translate into higher organ infiltration in SSc patients. Finally yet importantly, we characterised a novel function of the CD52 molecule on monocytes and its possible contribution during the course of the disease.


Disclosure: M. Rudnik, None; M. Stellato, None; F. Rolski, None; P. Blyszczuk, None; K. Klingel, None; J. Henes, None; C. Feghali-Bostwick, None; O. Distler, A. Menarini, 5, Abbvie, Acceleron, 5, Acceleron Pharma, 5, Actelion, 2, 5, 8, Actelion Pharmaceuticals, 2, 5, 8, 9, Amgen, 5, AnaMar, 2, 5, Bayer, 2, 5, 8, 9, Biogen Idec, 2, 5, Blade Therapeutics, 5, Boehringer Ingelheim, 2, 5, 8, 9, Catenion, 5, 9, ChemomAb, 2, 5, ChemomAB, 5, CSL Behring, 5, Ergonex, 5, espeRare Foundation, 2, 5, Genentech/Roche, 2, 5, GlaxoSmithKline, 5, GSK, 2, 5, Holds Patent mir-29 for the treatment of systemic sclerosis, 9, Inventiva, 2, 5, iQvia, 5, Italfarmaco, 2, 5, Italfarmco, 5, Lilly, 2, 5, med, 5, 8, medac, 5, Medac, 2, 5, MedImmune, 2, 5, Medscape, 5, 8, 9, Menarini, 8, Mepha, 8, Mitsubishi Tanabe, 2, 5, Mitsubishi Tanabe Pharma, 2, 5, MSD, 5, 8, Novartis, 2, 5, 8, 9, Patent, 9, Patent issued, 9, Pfizer, 2, 5, 8, Pharmacyclics, 2, 5, Roche, 5, 8, 9, Sanofi, 2, 5, Sinoxa, 2, 5, Target Bio Science, 5, Target BioScience, 5, UCB, 2, 5, 9, UCB in the area of potential treatments of scleroderma and its complications, 2, 5; G. Kania, Bayer, 2, Actelion, 8, Boehringer Ingelheim, 8.

To cite this abstract in AMA style:

Rudnik M, Stellato M, Rolski F, Blyszczuk P, Klingel K, Henes J, Feghali-Bostwick C, Distler O, Kania G. Altered Expression of CD52 Facilitates Adhesion of Circulating CD14+ Monocytes in Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/altered-expression-of-cd52-facilitates-adhesion-of-circulating-cd14-monocytes-in-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/altered-expression-of-cd52-facilitates-adhesion-of-circulating-cd14-monocytes-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology